Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

3.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

4.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

5.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot